**Cystatin C Reduction Ratio as an Indicator for Adequacy of Hemodialysis**

Prof D. Emad Allam1, Prof. Mostafa Abd El Fattah El Ballat1, Prof. Mohammed Saeed Al Shourbagy2 and Bahaa Eldin Mostafa Abd Elrahman1

1Internal Medicine Department, Faculty of Medicine, Al Azhar University, Cairo, Egypt

2Clinical Pathology Department, Faculty of Medicine, Al Azhar University, Cairo, Egypt

Dr.bahaa1979@gmail.com

**Abstract:** Accurate measurement of adequacy of haemodialysis is essential for evaluation of the care provided to patients with end stage renal disease on regular haemodialysis. Adequacy of haemodialysis is often measured using urea reduction ratio or kt/v. The usefulness of serum cystatin C reduction as an indicator of adequacy of haemodialysis is not known with certainty, therefore the present study will be undertaken in order to evaluate the potential clinical utility of serum cystatin C determination in patients undergoing haemodialysis**.** Aim of the work: This study will be conducted on 40 patients with end stage renal disease on regular haemodialysis by measurement of serum cystatin C before and after dialysis session to evaluate cystatin C reduction ratio as an indicator for adequacy of haemodialysis compared to urea reduction ratio, and serum creatinine.

[Emad Allam, Mostafa Abd El Fattah El Balla, Mohammed Saeed Al Shourbagy and Bahaa Eldin Mostafa Abd Elrahman. **Cystatin C Reduction Ratio as an Indicator for Adequacy of Hemodialysis.** *Researcher* 2018;10(9):1-7]. ISSN 1553-9865 (print); ISSN 2163-8950 (online). <http://www.sciencepub.net/researcher>. 1. doi:[10.7537/marsrsj100918.01](http://www.dx.doi.org/10.7537/marsrsj100818.10).

**Keywords:** Cystatin C; Reduction; Ratio; Indicator; Adequacy; Hemodialysis

#

# 1. Introduction

Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are major health problems worldwide with dramatically increasing incidence and prevalence. The evaluation of glomerular filtration rate (GFR) is very important to diagnosis of CKD (Zhang and Rothenbacher, 2008).

Adequacy of hemodialysis improves patient survival, quality of life and biochemical outcomes and minimizes disease complications and hospitalizations. Blood tests, body weight and blood pressure are measured before and after hemodialysis. Single-pool Kt/V and urea reduction ratio (URR) are calculated. The targets based on the National Kidney Foundation Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines are Kt/V > 1.2 and URR>65% Attempts to achieve the desired goals are necessary. It is important to calculate Kt/V or URR and individualize the dialysis doses for each patient (Adas et al., 2012).

Serum cystatin C (Scys-C) recently was proposed as a promising alternative marker of GFR owing to better specificity and sensitivity for detecting residual kidney function. However, several studies have reported that Scys-C was superior to serum creatinine as a marker of GFR (Pei et al., 2012).

Currently the determination of serum cystatin C has been proposed as an additional parameter for assessment of renal function. Cystatin C is a single non- glycosylated polypeptide chain consisting of 120 amino acid residues with a molecular mass of 13 kDa. Low molecular weight proteins are now recognized as a distinct class of uremic toxins and numerous compounds in this category have been identified including cystatin C. Serum cystatin C is produced at a constant rate by all nucleated cells and freely filtered by the glomerulus, it is neither secreted nor reabsorbed and has been known to be unaffected by non- renal factors. Therefore serum cystatin C is known to be an excellent surrogate marker of glomerular filtration rate (Ledson et al., 2008).

The usefulness of serum cystatin C levels as an indicator of the efficacy of hemodialysis is not known with certainty (Krishnamurthy et al., 2010). Therefore the present study will be undertaken in order to evaluate the potential clinical utility of serum cystatin C determination in patients undergoing hemodialysis.

**2. Materials and Methods**

**Inclusion crieteria:**

-End stage renal disease on regular haemodialysis

-Duration of haemodialysis more than one year

-Age =30 – 60 years

-Gender: male and female

**Exclusion crieteria:**

-Patients with sepsis

All patients will be subjected to the following:

1-Full history including duration of haemodialysis

2-Clinical examination

3-Investigations:

-Serum creatinine

-Blood urea

-Urea reduction ratio (URR): By measurement of blood urea before and after haemodialysis cession

-Glumerular filtration rate (GFR): By Cockroft Gault equation

-Cystatin C reduction ratio: By measurement of serum cystatin C before and after haemodialysis cession

-Complete blood count (CBC)

-Serum calcium

-Serum phosphorous

**3. Result:**

The study proved that serum cystatin C reduction ratio is highly significant as an indicator for adequacy of haemodialysis compared to urea reduction ratio and kt\v

The mean age of the studied sample was 49.78 ± 7.1 years and ranged from 31 – 59 years.

Table (1): Pre-dialysis and post-dialysis laboratory findings among the studied group

|  |  |  |
| --- | --- | --- |
| Parameter | Pre-dialysis | Post-dialysis |
| Mean ± SD | Range | Mean ± SD | Range |
| Albumin | 3.45 ± 0.51 | (2.3 – 4.3) | ND | ND |
| Hemoglobin | 10.28 ± 1.83 | (7.1 – 14.2) | ND | ND |
| Calcium | 8.43 ± 1.16 | (5.7 – 10.3) | ND | ND |
| Phosphorus | 4.42 ± 1.34 | (1.5 – 6.9) | ND | ND |
| Creatinine | 9.71 ± 2.36 | (4.8 – 13.6) | ND | ND |
| Blood urea | 127.95 ± 33.48 | (56 – 212) | 48.68 ± 16.7 | (21 – 94) |
| Urea reduction ratio | 61.74 ± 8.88 (33.71 – 78.38) |
| Cystatin C | 9.53 ± 7.46 | (1.5 – 50) | 4.13 ± 2.45 | (0.7 – 11.7) |
| Cystatin reduction ratio | 49.77 ± 28.12 (1.89 – 89.6) |

Table (2): Effectiveness of dialysis calculated in referral to Urea reduction ratio and Kt/V ratio

|  |  |  |
| --- | --- | --- |
| Parameter | Frequency | % |
| Urea reduction ratio | *Effective ≥ 65* | 14 | 35 |
| *Not effective ˂ 65* | 26 | 65.0 |
| Kt/V ratio | *Effective ≥ 1.2* | 40 | 100.0 |

Table (3): Correlation between blood chemistry before dialysis at one side and blood Urea & Cystatin before dialysis on the other hand

|  |  |  |
| --- | --- | --- |
| Parameter | Blood Urea | Cystatin |
| Pearson correlation | p-value | Pearson correlation | p-value |
| Hemoglobin | -0.14 | 0.39 | 0.09 | 0.6 |
| Albumin | -0.12 | 0.47 | 0.04 | 0.79 |
| Creatinin | 0.61 | 0.000 | 0.12 | 0.46 |
| Calcium | -0.38 | 0.016 | 0.17 | 0.3 |
| Phosphorus | 0.482 | 0.002 | -0.17 | 0.3 |

Table (4): Correlation between blood chemistry before dialysis at one side and blood Urea & Cystatin after dialysis on the other hand

|  |  |  |
| --- | --- | --- |
| Parameter | Blood Urea | Cystatin |
| Pearson correlation | p-value | Pearson correlation | p-value |
| Hemoglobin | -0.19 | 0.24 | -0.32 | 0.048 |
| Albumin | 0.04 | 0.83 | -0.07 | 0.66 |
| Creatinin | 0.28 | 0.08 | 0.16 | 0.32 |
| Calcium | -0.31 | 0.05 | -0.17 | 0.3 |
| Phosphorus | 0.33 | 0.037 | -0.26 | 0.1 |

Table (5): Correlation between blood chemistry before dialysis at one side and Urea RR & CysCRR on the other hand

|  |  |  |
| --- | --- | --- |
| Parameter | Urea RR | CysCRR |
| Pearson correlation | p-value | Pearson correlation | p-value |
| Hemoglobin | 0.053 | 0.75 | 0.316 | 0.047 |
| Albumin | -0.184 | 0.26 | 0.014 | 0.93 |
| Creatinin | 0.252 | 0.12 | -0.092 | 0.57 |
| Calcium | 0.081 | 0.62 | 0.19 | 0.24 |
| Phosphorus | 0.03 | 0.86 | -0.012 | 0.94 |

Table (6): Correlation between blood Urea and Cystatin levels before and after dialysis

|  |  |  |
| --- | --- | --- |
| Parameter | Pearson Correlation | p-value |
| Blood urea # Cystatin (before) | -0.07 | 0.68 |
| Blood urea # Cystatin (after) | 0.00 | 1.0 |
| Urea reduction ratio # Cystatin reduction ratio | 0.29 | 0.07 |

Table (7): Correlation between Urea reduction ratio & Cystatin reduction ratio with Kt/V ratio

|  |  |  |
| --- | --- | --- |
| Parameter | Pearson Correlation | p-value |
| Urea reduction ratio # Kt/V | 0.26 | 0.11 |
| Cystatin reduction ratio # Kt/V | 0.43 | 0.006 |

Table (8): Mean CysCRR in relation to abnormalities among laboratory tests done before dialysis

|  |  |  |
| --- | --- | --- |
| Parameter | CysCRR Mean ± SD | Significance |
| t-test | p-value |
| Hemoglobin | normal (n=16) | 63.2 ± 24.27 | 2.65 | 0.012 |
| abnormal (n=24) | 40.8 ± 27.35 |
| Albumin | normal (n=25) | 48.4 ± 29.98 | 0.395 | 0.7 |
| abnormal (n=15) | 52.1 ± 25.56 |
| Calcium | normal (n=28) | 52.55 ± 26.56 | 0.96 | 0.35 |
| abnormal (n=12) | 43.27 ± 31.73 |
| Phosphorus | normal (n=28) | 50.86 ± 28.13 | 0.37 | 0.71 |
| abnormal (n=12) | 47.23 ± 29.17 |

|  |  |  |
| --- | --- | --- |
| Variable | Effective dialysis URR ≥ 65%(n= 14) | Non effective dialysis URR ˂ 65%(n= 26) |
| Cystatin reduction ratio | 63.96 ± 24.35 | 42.13 ± 27.42  |
| t-test = 2.49 P-value = 0.017 |
| ROC curve (AUC)\* | 0.717 |
| Sensitivity in relation to URR  | 0.71 |
| Specificity in relation to URR | 0.62 |

Table (9): Comparison between mean Cystatin reduction ratio among the studied group regarding the resultant Urea reduction ratio (OR: according to dialysis effectiveness calculated by Urea RR)

\* ROC = Receiver Operating Characteristic – AUC = area under the curve

**4. Discussion**

Cystatin C is a low molecular mass plasma protein, which is synthesized and secreted constantly by all nucleated cells, it is freely filtered through the glomerulus and almost completely reabsorbed and catabolized by tubular cells, such that it will not return to the blood in an intact form **(Ogawa et al., 2008).**

There is strong association of serum cystatin C with mortality and cardiovascular disease than serum creatinine, particularly in studies of older adults **(Lesely et al., 2009).**

This prospective study was conducted in January 2016 on end stage renal disease patients that were on regular haemodialysis in Sidnawy health insurance hospital in Cairo.

Total number of cases was 40, our study was performed to assess usefulness of the use of cystatin C reduction ratio as an indicator of adequacy of haemodialysis.

In this study, our patients were chosen according to specific crieteria such as:

Inclusion crieteria:

1. End stage renal disease on regular haemodialysis for a period longer than one year.
2. Age between 30 – 60 years old
3. Gender: male and female

Exclusion crieteria:

1. Patients with acute renal failure
2. Pregnancy
3. Patients with sepsis

Our patients were informed about the study, they gave consent then we started our study

1. Full history including clinical diseases, duration of haemodialysis, cause of renal failure.
2. Clinical examination, general and abdominal examination
3. Laboratory investigations:

-Before starting haemodialysis session: blood haemoglobin, blood urea, serum creatinin, serum calcium, serum phosphorous, serum cystatin C.

-After haemodialysis session: Blood urea, serum cystatin C.

4- After collecting lab results, calculation of urea reduction ratio (URR), kt\v and cystatin C reduction ratio was done and results are listed and then, by statistical analysis the following results were obtained:

**Conclusion**:

We conclude that serum cystatin C reduction ratio can be a useful marker for assessment of adequacy of haemodialysis in patients with end stage renal disease on regular haemodialysis.

**References**

1. *Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, L undwall A, Jensson O, et al., (1990):* Structure and expression of the human cystatin C gene. Biochem J 268: 287–94.
2. *Aras O, Tsai MY, Hanson NQ et al., (2001*): Cystatin C is an independent predictor of fasting and post-methionine load total homocysteine concentrations among stable renal transplant recipients. Clin Chem; 47: 1263–1268.
3. *Arije A, Kadiri S & Akinkugbe* *OO, (2000):* The viability of hemodialysis as a treatment option for renal failure in a developing economy. *Afr* *J Med Med Sci.*; 29: 311–314.
4. *Arnaldi G & Angeli A, (2003):* Diagnosis and complications of Cushing’s syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism; 88: 5593–5602.
5. *Bamgboye EL, (2003):* Hemodialysis: management problems in developing countries, with Nigeriaas a surrogate. *Kidney Int.*; 63: 83-93.
6. *Bandaranayake, N.; Ankrah-Tetteh, T.; Wijeratne, S, et al.*, *(2007):* Intraindividual variation in creatinine and cystatine C, clinical Chemistry Laboratory Medicine.45: 1237-1239.
7. *Barsoum, R. S.,* (2003): End-stage renal disease in North Africa. *Kidney Int.*;63: 111.
8. *Barsoum, R. S., (*2002): Overview: End-stage renal disease in the developing world. Artificial Organs; 26[9], 737-746.
9. *Benhore, P.; Grenz, A.; Hartmann j. T., et al., (2006):* Cystatine C a marker for assessment of glomerular filtration rate in patients with cisplatin chemotherapy, kidney Blood Pressure Research 29: 32-35.
10. *Beyer K, Lao JI, Gomez M et al., (2001):* Alzheimer’s disease and the cystatin C gene polymorphism: an association study. Neurosci Lett; 315: 17-20.
11. *Biancofiore G, Pucci, L, Cerutti E et al., (2006):* Cystatin C as a marker of renal function immediately after liver transplantation *Liver Transpl*.; 12: 285-291.
12. *Bios, E. and Du bios, D., (2000)*: Formula to estimate the approximate surface area if height and weight be known. Internal Medicine, 17: 863-871.
13. *Brady, H. R. & Wilcox, C. S.,* (*1999):* Therapy in nephrology and hypertension: A comparison to Brenner and Rector's the kidney. Philadelphia, Pennsylvania: USA: W.B. Saunders Company.
14. *Cannata- Andia, Passlick- Deetjen J, Ritz E*, (2000): Management of the renal patient: expert’s recommendations and clinical algorithms on renal osteodystrophy and cardiovascular risk factors. Nephrol Dial Transplant; 15 (Suppl 2): 1–57.
15. *Chen J, Muntner P, Hamm L et al.,* (2004): The metabolic syndrome and chronic kidney disease in U.S. adults. Annals of Internal Medicine; 140:167–174.
16. *Chew JSC, Saleem M, Florkowski CM et al., (2008):* Cystatin C—a paradigm of evidence based laboratory medicine. *Clin Biochem Rev*.; 29: 47-62.
17. *Chück O, Gottfriedova H, Maly J et al., (2002):* Glomerular filtration rate assessment in individuals after orthotopic liver transplantation based on serum cystatin C levels. *Liver Transpl.*; 8: 594-599.
18. *Cochran M & St John A, (1993)*: A comparison between estimates of GRF using 99mTc DTPA clearance and the approximation of Cockcroft and Gault. Aust NZ J Med; 23: 494–497.
19. *Cockcroft DW & Gault MH, (1976):* Prediction of creatinine clearance from serum creatinine. Nephron; 16: 31–41.
20. *Colao A, Pivonello R, Spiezia S, Faggiano A et al., (1999):* Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. Journal of Clinical Endocrinology and Metabolism; 84: 2664–2672.
21. Collins A, Xue JL, Ma JZ & Louis T, (2000): Estimating the number of patients and medicare cost for end stage renal disease in the US to the year 2010. *J Am Soc Nephrol*; 11: 133A.
22. *Coresh J, Astor B, McQuillan G., et al., (2002):* Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis. 39: 920-929.
23. *Cueto- Manzano AM, (2003):* Peritoneal dialysis in Mexico. *Kidney Int.*; 63:90.
24. *Daugirdas, J. T., Blake, P. G., & Ing, T. S., (2001): Handbook of dialysis*. (3rd ed.) Philadelphia: USA: Lippincott Williams & Wilkins.
25. *Davidsson P, Paulson L, Hesse C, Blennow K & Nilsson CL, (2001):* Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electrophoresis approach prior to mass spectrometry. Proteomics; 3:444–452.
26. *Delanaye P, Cavalier E, Saint-Remy A et al., (2008):* Discrepancies between creatinine-based and cystatin C-based equations in estimating prevalence of stage 3 chronic kidney disease in an elderly population. *Scand J Clin Lab Invest*; 2: 1-6. E-pub ahead of print.
27. *Deng A, Irizarry MC, Nitsch RM, Growdon JH & Rebeck GW, (2001):* Elevation of cystatin C in susceptible neurons in Alzhei-mer’s disease. Am J Pathol; 159: 1061–1068.
28. *Dennis, E. and Alan, R. F., (2005):* Computation of the glomerular filtration rate with Tc-DPTA: an in house computer program. Journal Of Nuclear Medicine. 25; 613-618.
29. *Donahue, R.P.; Stranges, S.; Rejman, K., et al., (2007)*: Elevated cystatin C concentration and progression to pre- diabetes: the Western New Yourk Study. Diabetes Care.30: 1724-1729.
30. *Edmund, L, (2007):* Assessment of kidney function in adults. Laboratory investigations. Clinical Biochemistry.34: 359-364.
31. *Eknoyan G & Levin NW, (2000*): NKF K/DOQI Clinical practice guidelines for Nutrition in Chronic Renal Failure. Am J Kidney Dis; 35 w Suppl 2x: S1–S140.
32. *Emilio, R.; Gema, Ferna”ndez F.; Olga, C., et al., (2007):* Estimation of renal function in adult kidney transplant recipients by equations. Transplantation reviews. 21: 1-16.
33. *European best practice guidelines for the management of anaemia in patients with chronic renal failure, (1999):* Nephrol Dial Transplant; 14 (Suppl 5): 1–50.
34. *Faggiano A, Pivonello R, Melis D et al., (2002*): Evaluation of circulating levels and renal clearance of natural amino acids in patients with Cushing’s disease. Journal of Endocrinological Investigation; 25:142–151.
35. *Faggiano; A., Pivonello; R., Filippella; M. et al., (2003)*: Nephrolithiasis in Cushing’s disease: prevalence, ethiopathogenesis and modification after disease cure. Journal of Clinical Endocrinology and Metabolism; 88:2076–2080.
36. *Fan PY & Schwab SJ, (1992):* Vascular access: concepts for the 1990s. J Am Soc Nephrol; 3: 1–11.
37. *Fernando Liano,* ch 8 Acute renal failure causes & prognosis, Atlas of kidney diseases, vol 1, eds Tomas Berl and Joseph V. Bon Ventre, page 8-4, brought by ISN informatics commission.
38. *Filler. G. and lepage, N. (2003):* Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Pediatric Nephrology. 18: 981-985.
39. *Finney, H. Newman, D, J.; Thakkar, H., et al. (2000)*: Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children, Archives of Disease in Children. 82: 71-75.
40. *Fisher, M. and Veall, N. (1975):* Glomerular filtration rate estimation based on a single sample, British Medical Journal 2: 542.
41. *Fleming, J, S.; Zivanovic, M. A.; blake, G. M., et al (2004):* Guidelines for the measurement of glomerular filtration rate using plasma sampling. Nuclear Medicine.25: 759-769.
42. *Fliser, D. and Ritz, E. (2001)*: Serum cystatin C concentration as a marker of renal dysfunction in the elderly. American Journal of Kidney Disease. 37: 79-83.
43. *Fogazzi GB, Attolou V, Kadiri SL, et al. (2003):* A nephrological program in Benin and Togo (West Africa). *Kidney Int.*; 63: 56.
44. *Fricker M, Wiesli P, Brändle M et al., (2003):* Impact of thyroid dysfunction on serum cystatin C. *Kid Intern*.; 63: 1944-1947.
45. *Fricker, M.; Wiesli, p.; Brandle, M., et al. (2003):* Impact of thyroid dysfunction on serum cystatin C, Kidney International.63: 1944-1947.
46. *Ganong, W. F. (2001):* Review of medical physiology. (20th ed.) New York: USA: The McGraw-Hill Companies, Inc.
47. *Gerard SK, Khayam-Bashi H., (1985):* Characterization of creatinine error in ketotic patients. A prospective comparison of alkaline picrate methods with an enzymatic method. Am J Clin Pathol 84: 659– 664.
48. *Greenberg, A., Cheung, A. K., Coffmann, T. M., Falk, R. J., & Jennette, J. C., (1998):* Primer on kidney diseases. (2nd ed.) San Diego: California: Academic Press.
49. *Greenblatt SH, (2003):* Harvey Cushing’s paradigmatic contribution to neurosurgery and the evolution of his thought on his specialisation. Bulletin of the History of Medicine; 77: 789–822.
50. *Gresser O, Weber E, Hellwig A, Riese S & Regnier-Vigouroux A, (2001):* Immunocompetent astrocytes and microglia display major differences in the processing of the invariant chain and in the ex­pression of active cathepsin L and cathepsin S. Eur J Immunol;31: 1813–1824.
51. *Grubb A, Nyman U, Björk J et al., (2005):* Simple cystatin C–based prediction equations for glomerular filtration rate compared with the Modification of Diet in Renal Disease prediction equation for adults and the Schwartz and the Counahan–Barratt prediction equations for children. *Clin Chem*.; 51: 1420-1431.
52. *Grubb AO. (2000):* Cystatin C- properties and use as a diagnostic marker. Adv Clin Chem; 35: 63–99.
53. *Haase-Fielitz A, Bellomo R, Devarajan P et al., (2009*): Novel and conventional serum biomarkers predicting acute kidney injury in adult cardi*a*c surgery a prospective cohort study. *Crit Care Med*. E-pub ahead of print.
54. *Han H, Dwyer JT, Selhub Jet al., (2001):* Serum cystatin C is an independent predictor of total ho­mocysteine levels in stable Korean renal transplant recipients with normal serum creatinine. J Ren Nutr; 11: 149–154.
55. *Han, H.; Dwyer, J. T.; Selhub, J., et al., (2001):* Serum cystatin C is an independent predictor of total homocysteine levels in stable Korean renal transplant recipients with normal serum creatinine. Journal of Renal Nutrition. 11: 149-154.
56. *Henrich, W. L. (1999):* Principles and practice of dialysis. (2nd ed.) Baltimore, Maryland: USA.
57. *Herget-Rosenthal S, Marggraf G, Hüsing J et al., (2004)*: Early detection of acute renal failure by serum cystatin C. *Kidney Intl.*; 66: 1115-1122.
58. *Heymsfield SB, Arteaga C, Maccanus C, Smith J, Moffitt S., (1983):* Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. Am J Clin Nutr,;37: 478–94.
59. *Hoek, F. J.; Kemperman, F. A.; Krediet, R. T. (2003):* A comparison between cystatin C, plasma creatinine and the Cockroft and Gault formula for the estimation of glomerular filtration rate. Nephrology Dialysis Transplantation. 18: 2024-2031.
60. *Hoffmann U, Fischereder M, Kruger B et al., (2004):* The value of *N*-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. *J Am So.*
61. *Hricik, D. E., Miller, R. T., & Sedar, J. R., (2003):* Nephrology secrets. (2nd ed.) Philadelphia: USA: Hanley & Belfus, Inc.
62. *Hutin YJF, Goldstein ST, Varma JK et al., (1999):* An outbreak of hospital-acquired hepatitis B virus infection among patients receiving chronic hemodialysis. Infect Control Hosp Epidemiol; 20: 731–735.
63. *Ihle BU, Whitworth JA, Shahinfar S et al., (1996*): Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis; 27: 489–495.
64. *Irlando R, Mussap M, Plebani M et al., (2002):* Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. *Clin Chemistry*.; 48: 850-858.
65. *Izumihara A, Ishihara T, Hoshii* *Y & Ito H, (2001):* Cerebral amyloid angiopathy associated with hemorrhage: immunohistochemical study of 41 biopsy cases. Neurol Med Chir (Tokyo) 41, 471–477, discussion 477–478 c Nephrol 2004; 15:407–410.
66. *Jackson, J.; Blue, P. W. and Ghaed, N, (1985):* GFR determined in conjugation with routine renal scanning, Radiology. 154: 203-205.
67. *James GD, Sealey JE, Alderman M, Ljungman S, Mueller FB, et al., (1988):* A longitudinal study of urinary creatinine and creatinine clearance in normal subjects. Race, sex, and age differences. Am J Hypertens 1: 124– 131.
68. *Janice, S. C. C.; Mohammed, S.; Chrstopher M. F., et al., (2008):* Cystatin C-A paradigm of Evidence Based Laboratory Medicine, Clinical Biochemistry. 29: 47-62.
69. *Jerums G, Premaratne E, Panagiotopoulos* *S, et al., ( 2008)*: New and old markers of progression of diabetic nephropathy. *Diabetes Res Clin Pract.*; 82(suppl 1): S30-S37.
70. *Journal Of American Society Of Nephrology, (2002);*13 2140-2144
71. *K/DOQI clinical practice guidelines for chronic kidney disease, (2002):* evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis.; 39: S1-246. [PMID: 11904577].
72. *Kasiske BL, Kalil RS, Ma JZ, Liao M & Keane WF, (1993):* Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med; 118: 129–138.
73. *Kasiske BL, (1998):* Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis; 32 w Suppl 3x: S142–S156.
74. *Keller T, Martina Messow C, Lubos E et al., (2009)*: Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the Athero Gene study. *Eur Heart J.*; 30: 314-320.
75. *Kidney International, (2005):* vol. 67, P.2089-2100.
76. *Klahr S, Levey AS, Beck GJ et al., (1994):* The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med; 330: 877–884.
77. *Knight, E. L.; Verhave, J. C.; Spigelman, D.; et al., (2004):* Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney International. 65: 1416-1421.
78. *Koh J-M, Kim JY, Park JY et al., (2000):* Increased urinary albumin excretion in Cushing’s syndrome: remission after correction of hypercotisolemia. Clinical Endocrinology;52: 349–353.
79. *Kumar, P. & Clark, M., (2004):* Kumar & Clark clinical medicine. (5th ed.) Edinburgh: W.B. Saunders.
80. *Laterza, O. F.; Price, C. P. and Scott, M. G. (2002):* Cystatin C: an improved estimator of glomerular filtration rate. Clinical Chemistry. 48: 699-707.
81. *Lazarus JM, Bourgoignie JJ, Buckalew* *VM et al., (1997):* Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension; 29: 641– 650.
82. *Le Bricon T,* *Thervet E, Benlakeha M et al., (1999):* Changes in plasma cystatin C after renal transplantation and acute rejection in adults. *Clin Chem*.; 45: 2243-2249.
83. *Le Bricon T, Thervet E, Froissart M et al., (2000):* Plasma cystatin C is superior to 24-h creatinine clearance and plasma creatinine for estimation of glomerular filtration rate 3 months after kidney transplantation. *Clin Chem*.; 46: 1206-1207.
84. *Le Bricon T, Thervet E, Froissart M, Benlakehal M, Bousquet B, et al., (2000):* Plasma cystatin C is superior to creatinine clearance for estimation of GFR three months after kidney transplantation. Clin Chem 46: 1206–1207.
85. *Le Bricon, T.; Thervet, E.; Froissart, M., et al., (2000)*: Plasma cystatin C is superior to 24- h creatinine clearance and plasma creatinine for estimation of glomerular filtration rate 3 months after kidney transplantation. Clinical Chemistry. 46: 1206-1207.
86. Lefebvre A, de Vernejoul MC, *Gueris J et al.,* *(1989):* Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int; 36: 1112–1118.
87. *Leoncini G, Viazzi F, Parodi D, Vettoretti S & Ratto E, (2003):* Mild renal dysfunction and subclinical cardiovascular damage in primary hypertension. Hypertension; 42:14–18.
88. *Levey A.S.; Coresh, J.; Greene, T., et al., (2007):* Expressing the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clinical Chemistry. 53: 766-772.
89. *Levey AS & Greene T. (2000):* Simplified equation to predict glomerular filtration rate from serum creatinine. Am J Soc Nephrol. 11: 155A.
90. *Levey AS, Berg RL, Gassman JJ, Hall PM & Walker WG., (1989):* Creatinine filtration, secretion and excretion during progressive renal disease. Kidney Int 36(Suppl 27): S 73–80.
91. *Levey AS, Bosch JP, Breyer Lewis J, et al., (1999):* A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med;130: 461– 470.

9/17/2018